UNSPSC 51391729: Midodrine

This classification denotes an alpha-adrenergic agonist with the molecular formula C12H18N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6YE7PBM15H, chemically known as 2-amino-n-(2,5-dimethoxy-beta-hydroxyphenethylacetamide but generally known as midodrine, which bears US NIH Compound Identifier 4195. European Medicines Agency schedules Midodrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08954MIG.

UNSPSC 51391729 Midodrine is a Commodity code representing pharmaceutical products procured by state and local health agencies, though recent solicitations tagged under this code show significant scope mismatch. Seminole County, Florida's IFB60459723LAS solicited naloxone and drug deactivation systems rather than midodrine specifically, and the Texas Health and Human Services Commission's RFI HHS0017013 sought vendor capabilities for a direct-to-manufacturer prescription program without naming a particular pharmaceutical product. State and local buyers under this taxonomy include county health departments and state health and human services commissions operating community health initiatives, emergency response programs, and pharmacy benefit administration.

Geographic activity centers on Florida and Texas based on recent postings. Seminole County's naloxone procurement (due Jul 26, 2023, with quarterly deliveries to 520 W. Lake Mary Blvd, Sanford) represents a direct commodity purchase with E-Verify compliance, workers' compensation insurance, and potential FEMA funding attached. The Texas HHS Commission's RFI (posted Apr 3, 2026, response due Apr 3, 2026) is exploratory rather than a binding solicitation, designed to gather vendor intelligence on direct contracting models and negotiated net pricing before issuing a formal RFP. The mismatch between the code's nominal scope (midodrine, a vasoconstrictor medication) and the actual work being solicited (naloxone, drug deactivation systems, and pharmacy benefit program design) suggests the code sees limited targeted activity aligned with its stated pharmaceutical name, or classification errors in how opportunities are tagged at the source.